Stock Research for CMRX


Featured Broker: Ally Invest

Get the due diligence for another stock.


CMRX Stock Chart & Research Data

The CMRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CMRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CMRX Due diligence Resources & Stock Charts

The CMRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CMRX Detailed Price Forecast - CNN Money CNN View CMRX Detailed Summary - Google Finance
Yahoo View CMRX Detailed Summary - Yahoo! Finance Zacks View CMRX Stock Research & Analysis -

Stock Analysis

TradeIdeas View CMRX Trends & Analysis - Trade-Ideas Barrons View CMRX Major Holders - Barrons
NASDAQ View CMRX Call Transcripts - NASDAQ Seeking View CMRX Breaking News & Analysis - Seeking Alpha
Spotlight View CMRX Annual Report - OTC Report View CMRX OTC Short Report -
TradeKing View CMRX Fundamentals - TradeKing Charts View CMRX SEC Filings - Bar Chart
WSJ View Historical Prices for CMRX - The WSJ Morningstar View Performance/Total Return for CMRX - Morningstar
MarketWatch View the Analyst Estimates for CMRX - MarketWatch CNBC View the Earnings History for CMRX - CNBC
StockMarketWatch View the CMRX Earnings - StockMarketWatch MacroAxis View CMRX Buy or Sell Recommendations - MacroAxis
Bullish View the CMRX Bullish Patterns - American Bulls Short Pains View CMRX Short Pain Metrics -

Social Media Mentions

StockTwits View CMRX Stock Mentions - StockTwits PennyStocks View CMRX Stock Mentions - PennyStockTweets
Twitter View CMRX Stock Mentions - Twitter Invest Hub View CMRX Investment Forum News - Investor Hub
Yahoo View CMRX Stock Mentions - Yahoo! Message Board Seeking Alpha View CMRX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CMRX - Insider Cow View Insider Transactions for CMRX - Insider Cow
CNBC View CMRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CMRX - OTC Markets
Yahoo View Insider Transactions for CMRX - Yahoo! Finance NASDAQ View Institutional Holdings for CMRX - NASDAQ

Stock Charts

FinViz View CMRX Stock Insight & Charts - StockCharts View CMRX Investment Charts -
BarChart View CMRX Stock Overview & Charts - BarChart Trading View View CMRX User Generated Charts - Trading View

Latest Financial News for CMRX

Chimerix to Host Annual Investor Update on October 17, 2018
Posted on Thursday October 11, 2018

DURHAM, N.C., Oct. 11, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host.

How Should You Think About Chimerix Inc’s (NASDAQ:CMRX) Risks?
Posted on Thursday October 11, 2018

If you’re interested in Chimerix Inc (NASDAQ:CMRX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact

Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek
Posted on Friday October 05, 2018

Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascending doses (MAD) of intravenous (IV) brincidofovir (BCV) in healthy subjects. “This study shows that four weekly or twice-weekly doses of the IV formulation of brincidofovir are generally well tolerated, and the 10 mg dose provides similar blood levels as the oral 100 mg dose with no reported gastrointestinal side effects,” said Garrett Nichols, MD, MS, Chief Medical Officer of Chimerix.

Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Posted on Thursday October 04, 2018

Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the full analysis of adenovirus (AdV) viral load dynamics and all-cause mortality in pediatric patients. Prior to the AdVance study, the epidemiology of AdV after allo-HCT has been generally understood via single-center studies, with little data on the correlation between AdV viral load and risk of mortality. “AdVance represents a significant step forward in our understanding of the impact of adenovirus on allo-HCT recipients.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.